# Melengestrol.
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule, Technical Amendment.
**SUMMARY:**
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications and abbreviated new animal drug applications during March 2013. FDA is also informing the public of the availability of summaries the basis of approval and of environmental review documents, where applicable.
**DATES:**
This rule is effective April 30, 2013.
**FOR FURTHER INFORMATION CONTACT:**
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, *[email protected].*
**SUPPLEMENTARY INFORMATION:**
FDA is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during March 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: *http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.*
In addition, the animal drug regulations are being amended at 21 CFR 522.558 to add a new strength of dexmedetomidine hydrochloride injectable solution for use in dogs and cats. This change is being made to improve the accuracy of the regulations.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
| NADA/ANADA | Sponsor | New animal drug product name | Action | 21 CFR | FOIA summary | NEPA review |
| --- | --- | --- | --- | --- | --- | --- |
| 200-532 | Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria | TYLOVET 100 (tylosin phosphate) and MGA (melegestrone acetate) Type A medicated articles | Original approval as a generic copy of NADA 139-192 | 558.342 | yes | CE |
| 200-533 | Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria | TYLOVET 100 (tylosin phosphate) and RUMENSIN (monensin) and DECCOX (decoquinate) Type A medicated articles | Original approval as a generic copy of NADA 141-149 | 558.195 | yes | CE |
| 200-535 | Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria | TYLOVET 100 (tylosin phosphate) and BOVATEC (lasalocid) and MGA (melegestrone acetate) Type A medicated articles | Original approval as a generic copy of NADA 138-992 | 558.342 | yes | CE |
**List of Subjects**
Animal drugs.
Animal drugs, Animal feed.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 522 and 558 are amended as follows:
**21 CFR Part 522**
**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**
1. The authority citation for 21 CFR part 522 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 522**
2. In § 522.558, revise paragraph (a) to read as follows:
§ 522.558
(a) *Specifications.* Each milliliter of solution contains 0.5 or 1.0 milligrams dexmedetomidine hydrochloride.
**21 CFR Part 558**
**PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS**
3. The authority citation for 21 CFR part 558 continues to read as follows:
**Authority:**
21 U.S.C. 360b, 371.
**21 CFR Part 558**
4. In § 558.195, in the table, in paragraph (e)(2)(v), revise the last sentence in the “Limitations” column and revise the “Sponsor” column to read as follows:
§ 558.195
(e) * * *
(2) * * *
| Decoquinate in grams per ton | Combination in grams per ton | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| | | | | |
| * * * * * * * | | | | |
| (v) * * * | | | * * * Monensin as provided by No. 000986, and tylosin as provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter | 016592, 046573 |
| | | | | |
| * * * * * * * | | | | |
**21 CFR Part 558**
5. In § 558.342, in the table, in paragraphs (e)(1)(iv) and (e)(1)(ix), revise the last sentence in the “Limitations” column and revise the “Sponsor” column to read as follows:
§ 558.342
(e) * * *
(1) * * *
| Melengestrol acetate in mg/head/day | Combination in mg/head/day | Indications for use | Limitations | Sponsor |
| --- | --- | --- | --- | --- |
| | | | | |
| * * * * * * * | | | | |
| (iv) * * * | | | * * * Lasalocid provided by No. 046573, and tylosin provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter | 000009, 000986, 016592 |
| | | | | |
| * * * * * * * | | | | |
| (ix) * * * | | | Tylosin provided by Nos. 000986 and 016592 in § 510.600(c) of this chapter | 000009, 000986, 016592 |
Dated: April 25, 2013.
Bernadette Dunham,
Director, Center for Veterinary Medicine.